1. Worsening of COVID-19 after chemotherapy in patients considered to have recovered from a SARS-CoV-2 infection.
- Author
-
Poncelet, Arthur, Verschelden, Gil, Colard, Martin, Hildebrand, Marc, Hites, Maya, Yin, Nicolas, Michel, Charlotte, Grimaldi, David, and De Wilde, Virginie
- Subjects
- *
MANTLE cell lymphoma , *SARS-CoV-2 , *COVID-19 , *FEBRILE neutropenia , *DIFFUSE large B-cell lymphomas , *CANCER chemotherapy - Abstract
In another study, no reactivation was documented following chemotherapy in patients previously infected with SARS-CoV-2, but all patients had negative SARS-CoV-2 PCR on NPS and positive SARS-CoV-2 serology before receiving chemotherapy [[11]]. Given the increased risk of infection after chemotherapy, hematological societies have proposed postponing chemotherapy, when feasible, during the COVID-19 pandemic [[1]], despite initial studies showing no increase in the incidence of COVID-19 among hematological patients [[2]]. It is noteworthy that all three patients had negative serology for SARS-CoV-2 more than one month after their first positive PCR for SARS-CoV-2, suggesting that these patients were not able to develop a humoral immune response against SARS-CoV-2. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF